

## 9.0 References

Bastianello S, Pozzilli C, D'Andrea F, et al. A controlled trial of mitoxantrone in multiple sclerosis: Serial MRI evaluation at one year. *Can J Neurol Sci* 1994;21:266-70.

De Castro S, Cartoni D, Millefiorini E, et al. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. *J Clin Pharmacol* 1995;35:627-32.

Dukart G, Barone JS. An overview of cardiac episodes following mitoxantrone administration. *Cancer Treatment Symposia* 1984;3:35-39.

Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomized multicentre study of active disease using MRI and clinical criteria. *J Neurol Neurosurg Psychiatry* 1997;62:112-8.

Gams RA, Wesler MJ. Mitoxantrone cardiotoxicity: results from Southeastern Cancer Study Group. *Cancer Treatment Symposia* 1984;3:31-34.

Gonsette RE, Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: A pilot study for 2 years in 22 patients. *Neurology* 1990;40(Suppl 1):261. (Abstract 537P).

Hartung H-P, Gonsette R, MIMS Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind phase III trial: clinical results and three-year follow-up. *Neurology* 1999a;52(Suppl 2):A290. (Abstract S45.005).

Hartung H-P, Gonsette R, MIMS Study Group. Mitoxantrone in progressive multiple sclerosis (MS): Clinical results and three-year follow-up of the MIMS trial. *Mult Scler* 1999;5(Suppl 1):S15. (Abstract 56).

Hartung H, Gonsette R, MIMS Study Group. Mitoxantrone in progressive multiple sclerosis (MS): A placebo-controlled, randomized, observer-blind European phase III multicenter study -- Clinical results. *Mult Scler* 1998;4:98. (Abstract 207).

Kappos L, Gold R, Kunstler E, et al. Mitoxantrone (Mx) in the treatment of rapidly progressive MS: A pilot study with serial gadolinium (Gd)-enhanced MRI. Neurology 1990;40(Suppl 1):261. (Abstract 539P).

Krapf H, Mauch E, Fetzer U, et al. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 1995 37(2):113-9.

Krapf H, Morrissey SP, Zenker O, et al. Mitoxantrone in progressive multiple sclerosis (MS): A placebo-controlled, randomized, observer-blind European phase III multicenter study -- MRI results. Mult Scler 1998;4:380. (Abstract P3024).

Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996;46:907-11.

Mauch E, Kornhuber MH, Krapf H, et al. Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992;242:96-102.

Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-9.

Noseworthy JH, Hopkins MB, Vandervoort MK, et al. An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993;43:1401-6.

Ruggero C, Marciano N. Mitoxantrone therapy of secondary progressive multiple sclerosis: Pilot study. Neurology 1993;4(Suppl 2):A281. (Abstract 494S).